Opportunities in pharmacogenomics for the treatment of Alzheimer's disease

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Suehs BT, Davis CD, Alvir J et al. The clinical and economic burden of newly diagnosed Alzheimer's disease in a medicare advantage population. Am. J. Alzheimers Dis. Other Demen. 28(4), 384–392 (2013).
  MedlineGoogle Scholar
• 2 National Center for Health Statistics (NCHS). http://www.cdc.gov/nchs/.
  Google Scholar
• 3 Centers for Disease Control and Prevention (CDC). http://www.cdc.gov.
  Google Scholar
• 4 Herrmann N, Tam DY, Balshaw R et al. The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada. Can. J. Psychiatry 55(12), 768–775 (2010).
  MedlineGoogle Scholar
• 5 Cacabelos R. The path to personalized medicine in mental disorders. In: The Handbook Of Neuropsychiatric Biomarkers, Endophenotypes And Genes (Volume 6). Ritsner MS (Ed.). Springer, Dordrecht, The Netherlands, 3–63 (2011).
  Google Scholar
• 6 Cacabelos R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev. Mol. Diagn. 9(6), 567–611 (2009).
  Medline CASGoogle Scholar
• 7 Cacabelos R, Fernandez-Novoa L, Lombardi V, Kubota Y, Takeda M. Molecular genetics of Alzheimer's disease and aging. Methods Find. Exp. Clin. Pharmacol. 27(Suppl. A), 1–573 (2005).
  MedlineGoogle Scholar
• 8 Cacabelos R. Alzheimer's disease 2011: where are we heading? Gen-T 8, 54–86 (2011).
  Google Scholar
• 9 Cacabelos R, Takeda M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer's disease. Drugs Future 31(Suppl. B), 5–146 (2006).
  Google Scholar
• 10 Cacabelos R. Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics. Neuropsychiatr. Dis. Treat. 3(3), 303–333 (2007).
  Medline CASGoogle Scholar
• 11 Cacabelos R. Pharmacogenomics in Alzheimer's disease. Methods Mol. Biol. 448, 213–357 (2008).
  Medline CASGoogle Scholar
• 12 Cacabelos R, Martínez-Bouza R. Genomics and pharmacogenomics of dementia. CNS Neurosci. Ther. 17(5), 566–576 (2011).
  Medline CASGoogle Scholar
• 13 Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Expert Opin. Pharmacother. 6(12), 1967–1987 (2005).
  Medline CASGoogle Scholar
• 14 Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci. 258(Suppl. 1), 28–47 (2008).
  MedlineGoogle Scholar
• 15 Cacabelos R. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. Mol. Diagn. Ther. 11(6), 385–405 (2007).
  Medline CASGoogle Scholar
• 16 Cacabelos R, Llovo R, Fraile C, Fernández-Novoa L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr. Alzheimer Res. 4(4), 479–500 (2007).
  Medline CASGoogle Scholar
• 17 Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods Find. Exp. Clin. Pharmacol. 29(Suppl. A), 1–91 (2005).• Extensive paper with original data on the pharmacogenetics of Alzheimer's disease (AD).
  Google Scholar
• 18 Cacabelos R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer's disease. Aging Health 1, 303–348 (2005).
  CASGoogle Scholar
• 19 Loveman E, Green C, Kirby J et al. The clinical and cost–effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol. Assess. 10(1), 1–160 (2006).
  Google Scholar
• 20 Cacabelos R, Álvarez A, Lombardi V et al. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today (Barc.) 36(7), 415–499 (2000).
  Medline CASGoogle Scholar
• 21 Giacobini E. Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders. In: The Brain Cholinergic System In Health And Disease. Giacobini E, Pepeu G (Eds). Informa Healthcare, Oxon, UK, 235–264 (2006).
  Google Scholar
• 22 Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348(14), 1333–1341 (2003).
  Medline CASGoogle Scholar
• 23 Schenk DB, Seubert P, Grundman M, Black R. Aβ immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodegener. Dis. 2(5), 255–260 (2005).
  Medline CASGoogle Scholar
• 24 Wisniewski T, Boutajangout A. Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J. Med. 77(1), 17–31 (2010).
  MedlineGoogle Scholar
• 25 de Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6(2), 99–107 (2010).
  Medline CASGoogle Scholar
• 26 Shelton CC, Zhu L, Chau D et al. Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proc. Natl Acad. Sci. USA 106(48), 20228–20233 (2009).
  Medline CASGoogle Scholar
• 27 Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN. DNA beta-amyloid (1–42) trimer immunization for Alzheimer disease in a wild-type mouse mode. JAMA 302(16), 1796–1802 (2009).
  Medline CASGoogle Scholar
• 28 Carrera I, Etcheverría I, Fernández-Novoa L, Lombardi V, Cacabelos R, Vigo C. Vaccine development to treat Alzheimer's disease Neuropathology in APP/PS1 Transgenic Mice. Int. J. Alzheimers Dis. 2012, 376138 (2012).• Report on the generation of a dual vaccine (preventive/therapeutic) against AD.
  MedlineGoogle Scholar
• 29 Cacabelos R, Cacabelos P, Torrellas C, Tellado I, Carril JC. Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development. Meth. Mol. Biol. 1175, 323–556 (2014).•• The newest review on AD pharmacogenetics with over 600 different experimental products for the treatment of AD.
  MedlineGoogle Scholar
• 30 Kamble P, Chen H, Sherer JT, Aparasu RR. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging 26(6), 483–492 (2009).
  MedlineGoogle Scholar
• 31 Liperoti R, Onder G, Landi F et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J. Clin. Psychiatry 70(10), 1340–1347 (2009).
  MedlineGoogle Scholar
• 32 Wang J, Zhao Z, Lin E et al. Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease. PLoS ONE 8(6), e65232 (2013).
  Medline CASGoogle Scholar
• 33 Montastruc F, Gardette V, Cantet C et al. Potentially inappropriate medication use among patients with Alzheimer disease in the REAL. FR cohort: be aware of atropinic and benzodiazepine drugs! Eur. J. Clin. Pharmacol. 69(8), 1589–1597 (2013).
  MedlineGoogle Scholar
• 34 Cacabelos R. Pharmacogenomics of central nervous system (CNS) drugs. Drug Dev. Res. 73, 461–476 (2012).
  CASGoogle Scholar
• 35 Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39(1), 17–23 (2007).
  Medline CASGoogle Scholar
• 36 Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet. 3, 67–99 (2002).
  Medline CASGoogle Scholar
• 37 Suh YH, Checler F. Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54(3), 469–525 (2002).
  Medline CASGoogle Scholar
• 38 Larner AJ. Presenilin-1 mutations in Alzheimer's disease: an update on genotype-phenotype relationships. J. Alzheimers Dis. 37(4), 653–659 (2013).
  Medline CASGoogle Scholar
• 39 Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353–356 (2002).
  Medline CASGoogle Scholar
• 40 Hooli BV, Kovacs-Vajna ZM, Mullin K et al. Rare autosomal copy number variations in early-onset familial Alzheimer's disease. Mol. Psychiatry 19(6), 676–681 (2014).
  Medline CASGoogle Scholar
• 41 Cacabelos R, Fernández-Novoa L, Martínez-Bouza R et al. Future trends in the pharmacogenomics of brain disorders and dementia: influence of APOE and CYP2D6 variants. Pharmaceuticals 3(10), 3040–3100 (2010).
  CASGoogle Scholar
• 42 Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharm. Toxicol. 41, 815–850 (2001).
  Medline CASGoogle Scholar
• 43 World Guide for Drug Use and Pharmacogenomics. Cacabelos R (Ed.). EuroEspes Publishing, Corunna, Spain (2012).•• The first World Guide of Pharmacogenomics (more than 3000 pages, over 5000 products and 1500 genes).
  Google Scholar
• 44 Preissner S, Kroll K, Mathias M et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP–drug interactions. Nucleic Acids Res. 38(Database issue), D237–D243 (2010).
  Medline CASGoogle Scholar
• 45 Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414–417 (2012).
  Medline CASGoogle Scholar
• 46 Isaza CA, Henao J, López AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol. 22(9), 695–705 (2000).
  Medline CASGoogle Scholar
• 47 Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 35(2–3), 99–106 (2003).
  Medline CASGoogle Scholar
• 48 Ozawa S, Soyama A, Saeki M et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokin. 19(2), 83–95 (2004).
  Medline CASGoogle Scholar
• 49 Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7, 223–245 (2006).
  Medline CASGoogle Scholar
• 50 Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug–drug interactions. Curr. Drug Targets 12(5), 600–620 (2011).
  Medline CASGoogle Scholar
• 51 Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr. Drug Targets 12(5), 631–646 (2011).
  Medline CASGoogle Scholar
• 52 Li G, Gu HM, Zhang DW. ATP-binding cassette transporters and cholesterol translocation. IUBMB Life 65, 505–512 (2013).
  Medline CASGoogle Scholar
• 53 Cacabelos R, López-Muñoz F. The ABCB1 transporter in Alzheimer's disease. Clin. Exp. Pharmacol. 4, e128 (2014).
  Google Scholar
• 54 Reitz C, Jun G, Naj A et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4, and the risk of late-onset Alzheimer disease in African Americans. JAMA 309(14), 1483–1492 (2013).
  Medline CASGoogle Scholar
• 55 Abuznait AH, Kaddoumi A. Role of ABC transporters in the pathogenesis of Alzheimer's disease. ACS Chem. Neurosci. 3(11), 820–831 (2012).
  Medline CASGoogle Scholar
• 56 Wolf A, Bauer B, Hartz AM. ABC transporters and the Alzheimer's disease enigma. Front. Psychiatry 3, 54 (2012).
  MedlineGoogle Scholar
• 57 Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J. Alzheimers Dis. 31(1), 151–165 (2012).
  Medline CASGoogle Scholar
• 58 Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS ONE 7(11), e50976 (2012).
  Medline CASGoogle Scholar
• 59 van Assema DM, Lubberink M, Bauer M et al. Blood–brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135, 181–189 (2012).
  MedlineGoogle Scholar
• 60 Silverberg GD, Messier AA, Miller MC et al. Amyloid efflux transporter expression at the blood–brain barrier declines in normal aging. J. Neuropathol. Exp. Neurol. 69(10), 1034–1043 (2010).
  Medline CASGoogle Scholar
• 61 Fehér Á1, Juhász A, László A, Pákáski M, Kálmán J, Janka Z. Association between the ABCG2 C421A polymorphism and Alzheimer's disease. Neurosci. Lett. 550, 51–54 (2013).
  Medline CASGoogle Scholar
• 62 van Assema DM, Lubberink M, Rizzu P et al. Blood–brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Res. 2(1), 57 (2012).
  MedlineGoogle Scholar
• 63 Kohen R, Shofer JB, Korvatska O et al. ABCB1 genotype and CSF beta-amyloid in Alzheimer disease. J. Geriatr. Psychiatry Neurol. 24(2), 63–66 (2011).
  Medline CASGoogle Scholar
• 64 Frankfort SV, Doodeman VD, Bakker R et al. ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. Mol. Neurodegener. 1, 13 (2006).
  MedlineGoogle Scholar
• 65 Chen KD, Chang PT, Ping YH, Lee HC, Yeh CW, Wang PN. Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease. Neurobiol. Dis. 43(3), 698–705 (2011).
  Medline CASGoogle Scholar
• 66 Elali A, Rivest S. The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. Front. Physiol. 4, 45 (2013).
  MedlineGoogle Scholar
• 67 Cascorbi I, Flüh C, Remmler C et al. Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Pharmacogenomics 14(5), 485–494 (2013).
  CASGoogle Scholar
• 68 Namanja HA, Emmert D, Pires MM, Hrycyna CA, Chmielewski J. Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. Biochem. Biophys. Res. Commun. 388(4), 672–676 (2009).
  Medline CASGoogle Scholar
• 69 Cacabelos R. The metabolomics paradigm of pharmacogenomics in complex disorders. Metabolomics 2, e119 (2012).
  Google Scholar
• 70 Hosoya K, Tachikawa M. Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin. Exp. Nephrol. 15(4), 478–485 (2011).
  Medline CASGoogle Scholar
• 71 Carl SM, Lindley DJ, Couraud PO et al. ABC and SLC transporter expression and Pot substrate characterization across the human CMEC/D3 blood–brain barrier cell line. Mol. Pharm. 7(4), 1057–1068 (2010).
  Medline CASGoogle Scholar
• 72 Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41(10), 719–739 (2002).
  Medline CASGoogle Scholar
• 73 Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin. Pharmacokinet. 52(4), 225–241 (2013).•• Excellent paper on the pharmacokinetic and pharmacodynamic properties of selected antidementia drugs.
  Medline CASGoogle Scholar
• 74 Pilotto A, Franceschi M, D'Onofrio G et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 73, 761–767 (2009).
  Medline CASGoogle Scholar
• 75 Albani D, Martinelli Boneschi F, Biella G et al. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. J. Alzheimers Dis. 30(4), 745–749 (2012).
  Medline CASGoogle Scholar
• 76 Savino M, Seripa D, Gallo AP et al. Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. Clin. Lab. 57(11–12), 887–893 (2011).
  Medline CASGoogle Scholar
• 77 Seripa D, Bizzarro A, Pilotto A et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet. Genomics 21(4), 225–230 (2011).
  Medline CASGoogle Scholar
• 78 Zhong Y, Zheng X, Miao Y, Wan L, Yan H, Wang B. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease. Am. J. Med. Sci. 345(3), 222–226 (2013).
  MedlineGoogle Scholar
• 79 Varsaldi F, Miglio G, Scordo MG et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur. J. Clin. Pharmacol. 62(9), 721–726 (2006).
  Medline CASGoogle Scholar
• 80 Chianella C, Gragnaniello D, Maisano Delser P et al. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur. J. Clin. Pharmacol. 67(11), 1147–1157 (2011).
  Medline CASGoogle Scholar
• 81 Mannheimer B, Wettermark B, Lundberg M, Pettersson H, von Bahr C, Eliasson E. Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. Br. J. Clin. Pharmacol. 69(4), 411–417 (2010).
  Medline CASGoogle Scholar
• 82 Klimkowicz-Mrowiec A, Wolkow P, Sado M et al. Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with Alzheimer's disease. Neuropsychiatr. Dis. Treat. 9, 1029–1033 (2013).
  Medline CASGoogle Scholar
• 83 Magliulo L, Dahl ML, Lombardi G et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?. Eur. J. Clin. Pharmacol. 67, 47–54 (2011).
  Medline CASGoogle Scholar
• 84 Lilienfeld S. Galantamine: a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 8(2), 159–176 (2002).
  Medline CASGoogle Scholar
• 85 Farlow MR. Clinical pharmacokinetics of galantamine. Clin. Pharmacokinet. 42(15), 1383–1392 (2003).
  Medline CASGoogle Scholar
• 86 Zhao Q, Brett M, Van Osselaer N et al. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J. Clin. Pharmacol. 42(9), 1002–1010 (2002).
  Medline CASGoogle Scholar
• 87 Mannens GS, Snel CA, Hendrickx J et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab. Dispos. 30(5), 553–563 (2002).
  Medline CASGoogle Scholar
• 88 Noetzli M, Guidi M, Ebbing K et al. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. Ther. Drug Monit. 35(2), 270–275 (2013).
  Medline CASGoogle Scholar
• 89 Clarke JA, Cutler M, Gong I, Schwarz UI, Freeman D, Dasgupta M. Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study. Am. J. Geriatr. Pharmacother. 9(4), 224–233 (2011).
  Medline CASGoogle Scholar
• 90 Bentué-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 17(13), 947–963 (2003).
  Medline CASGoogle Scholar
• 91 Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. Curr. Clin. Pharmacol. 5(2), 115–124 (2010).
  Medline CASGoogle Scholar
• 92 Zhai XJ, Lu YN. Food–drug interactions: effect of capsaicin on the pharmacokinetics of galantamine in rats. Xenobiotica 42(11), 1151–1155 (2012).
  Medline CASGoogle Scholar
• 93 Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther. 20(4), 634–647 (1998).
  Medline CASGoogle Scholar
• 94 Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V. Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients. CNS Neurosci. Ther. 19(2), 91–97 (2013).
  Medline CASGoogle Scholar
• 95 Lupp A, Appenroth D, Fang L, Decker M, Lehmann J, Fleck C. Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine. Arzneimittelforschung 60(5), 229–237 (2010).
  Medline CASGoogle Scholar
• 96 Alfirevic A, Mills T, Carr D et al. Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenet. Genomics 17(12), 1091–1100 (2007).
  Medline CASGoogle Scholar
• 97 Yang Z, Zhou X, Zhang Q. Effectiveness and safety of memantine treatment for Alzheimer's disease. J. Alzheimers Dis. 36(3), 445–458 (2013).
  Medline CASGoogle Scholar
• 98 Micuda S, Mundlova L, Anzenbacherova E et al. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur. J. Clin. Pharmacol. 60(8), 583–589 (2004).
  Medline CASGoogle Scholar
• 99 Noetzli M, Guidi M, Ebbing K et al. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin. Pharmacokinet. 52(3), 211–223 (2013).
  Medline CASGoogle Scholar
• 100 Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 4(5), 597–621 (2003).
  CASGoogle Scholar
• 101 Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5(9), 645–656 (2004).• Pioneering proposals for drug development and pharmacogenetics of AD.
  Medline CASGoogle Scholar
• 102 Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat. Rev. Drug Discov. 7(10), 807–817 (2008).
  Medline CASGoogle Scholar
• 103 Roses AD. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(∗)5701 as a model of safety. Neuropsychopharmacology 34(1), 6–17 (2009).
  Medline CASGoogle Scholar
• 104 Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenic hypothesis (Alzheimer's disease). Pharmacogenomics J. 7(1), 10–28 (2007).
  Medline CASGoogle Scholar
• 105 Risner ME, Saunders AM, Altman JF et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6(4), 246–254 (2006).
  Medline CASGoogle Scholar
• 106 Takei N, Miyashita A, Tsukie T et al. Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. Genomics 93(5), 441–448 (2009).
  Medline CASGoogle Scholar
• 107 Potkin SG, Guffanti G, Lakatos A et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS ONE 4(8), e6501 (2009).
  MedlineGoogle Scholar
• 108 Roses AD. An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch. Neurol. 67(5), 536–541 (2010).
  MedlineGoogle Scholar
• 109 Roses AD, Lutz MW, Amrine-Madsen H et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J. 10(5), 375–384 (2010).• First report on the effect of TOMM40 variants on the age at onset in patients with AD.
  Medline CASGoogle Scholar
• 110 Roses AD, Saunders AM, Lutz MW et al. New applications of disease genetics and pharmacogenetics to drug development. Curr. Opin. Pharmacol. 14, 81–89 (2014).
  Medline CASGoogle Scholar
• 111 Roses AD, Lutz MW, Crenshaw DG, Grossman I, Saunders AM, Gottschalk WK. TOMM40 and APOE: requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. Alzheimers Dement. 9(2), 132–136 (2013).
  MedlineGoogle Scholar
• 112 Lutz MW, Crenshaw DG, Saunders AM, Roses AD. Genetic variation at a single locus and age of onset for Alzheimer's disease. Alzheimers Dement. 6(2), 125–131 (2010).
  Medline CASGoogle Scholar
• 113 Shen L, Kim S, Risacher SL et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: a study of the ADNI cohort. Neuroimage 53(3), 1051–1063 (2010).
  Medline CASGoogle Scholar
• 114 Linnertz C, Saunders AM, Lutz MW et al. Characterization of the poly-T variant in the TOMM40 gene in diverse populations. PLoS ONE 7(2), e30994 (2012).
  Medline CASGoogle Scholar
• 115 Omoumi A, Fok A, Greenwood T, Sadovnick AD, Feldman HH, Hsiung GY. Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. Neurobiol. Aging 35, 936.e5–12 (2014).
  CASGoogle Scholar
• 116 Bagnoli S, Piaceri I, Tedde A et al. TOMM40 polymorphisms in Italian Alzheimer's disease and frontotemporal dementia patients. Neurol. Sci. 34(6), 995–998 (2013).
  MedlineGoogle Scholar
• 117 Ma XY, Yu JT, Wang W et al. Association of TOMM40 polymorphisms with late-onset Alzheimer's disease in a Northern Han Chinese population. Neuromolecular. Med. 15(2), 279–287 (2013).
  Medline CASGoogle Scholar
• 118 Valant V, Keenan BT, Anderson CD et al. TOMM40 in cerebral amyloid angiopathy related intracerebral hemorrhage: comparative genetic analysis with Alzheimer's disease. Transl. Stroke Res. 3(Suppl. 1), 102–112 (2012).
  Medline CASGoogle Scholar
• 119 Vounou M, Janousova E, Wolz R et al. Sparse reduced-rank regression detects genetic associations with voxel-wise longitudinal phenotypes in Alzheimer's disease. Neuroimage 60(1), 700–716 (2012).
  MedlineGoogle Scholar
• 120 Bernardi L, Gallo M, Anfossi M et al. Role of TOMM40 rs10524523 polymorphism in onset of Alzheimer's disease caused by the PSEN1 M146L mutation. J. Alzheimers Dis. 37(2), 285–289 (2013).
  Medline CASGoogle Scholar
• 121 Sebastiani P, Solovieff N, Dewan AT et al. Genetic signatures of exceptional longevity in humans. PLoS ONE 7, e29848 (2012).
  Medline CASGoogle Scholar
• 122 Beekman M, Blanché H, Perola M et al. Genome-wide linkage analysis for human longevity: Genetics of Healthy Aging Study. Aging Cell 12(2), 184–193 (2013).
  Medline CASGoogle Scholar
• 123 Zhang C, Pierce BL. Genetic susceptibility to accelerated cognitive decline in the US Health and Retirement Study. Neurobiol. Aging 35(6), 1512.e11–8 (2014).
  Google Scholar
• 124 Davies G, Harris SE, Reynolds CA et al. A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing. Mol. Psychiatry 19(1), 76–87 (2014).
  Medline CASGoogle Scholar
• 125 Hayden KM, McEvoy JM, Linnertz C et al. A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. Alzheimers Dement. 8(5), 381–388 (2012).
  Medline CASGoogle Scholar
• 126 Linnertz C, Anderson L, Gottschalk W et al. The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes. Alzheimers Dement. S1552–5260(13), 02801-X (2014).
  Google Scholar
• 127 Lyall DM, Harris SE, Bastin ME et al. Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. Neurobiol. Aging 35(6), 1513.e25–33 (2014).
  CASGoogle Scholar
• 128 Johnson SC, La Rue A, Hermann BP et al. The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. Alzheimers Dement. 7(4), 456–465 (2011).
  Medline CASGoogle Scholar
• 129 Elias-Sonnenschein LS, Helisalmi S, Natunen T et al. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case–control cohort. PLoS ONE 8(4), e59676 (2013).
  Medline CASGoogle Scholar
• 130 Silver M, Janousova E, Hua X, Thompson PM, Montana G. Alzheimer's disease neuroimaging initiative: identification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression. Neuroimage 63(3), 1681–1694 (2012).
  Medline CASGoogle Scholar
• 131 Kim S, Swaminathan S, Shen L et al. Genome-wide association study of CSF biomarkers Abeta1–42, t-tau, and p-tau181p in the ADNI cohort. Neurology 76(1), 69–79 (2011).
  Medline CASGoogle Scholar
• 132 Bruno D, Pomara N, Nierenberg J et al. Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants. Exp. Gerontol. 47(5), 347–352 (2012).
  Medline CASGoogle Scholar
• 133 McFarquhar M, Elliott R, McKie S et al. TOMM40 rs2075650 may represent a new candidate gene for vulnerability to major depressive disorder. Neuropsychopharmacology 39(7), 1743–1753 (2014).
  Medline CASGoogle Scholar
• 134 Mastaglia FL, Rojana-udomsart A, James I et al. Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromusc. Disord. 23(12), 969–974 (2013).
  Medline CASGoogle Scholar
• 135 Seripa D, Bizzarro A, Pilotto A et al. TOMM40, APOE, and APOC1 in primary progressive aphasia and frontotemporal dementia. J. Alzheimers Dis. 31(4), 731–740 (2012).
  Medline CASGoogle Scholar
• 136 Ellis J, Lange EM, Li J et al. Large multiethnic candidate gene study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. Hum. Genet. 133(8), 985–995 (2014).
  Medline CASGoogle Scholar
• 137 Zhou L, He M, Mo Z et al. A genome wide association study identifies common variants associated with lipid levels in the Chinese population. PLoS ONE 8(12), e82420 (2013).
  MedlineGoogle Scholar
• 138 Zhang Z, Tao L, Chen Z et al. Association of genetic loci with blood lipids in the Chinese population. PLoS ONE 6(11), e27305 (2011).
  Medline CASGoogle Scholar
• 139 Jiang R, Brummett BH, Hauser ER et al. Chronic family stress moderates the association between a TOMM40 variant and triglyceride levels in two independent Caucasian samples. Biol. Psychol. 93(1), 184–189 (2013).
  MedlineGoogle Scholar
• 140 Guo Y, Lanktree MB, Taylor KC et al. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. Hum. Mol. Genet. 22(1), 184–201 (2012).
  MedlineGoogle Scholar
• 141 Middelberg RP, Ferreira MA, Henders AK et al. Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. BMC Med. Genet. 12, 123 (2011).
  MedlineGoogle Scholar
• 142 Jeemon P, Pettigrew K, Sainsbury C, Prabhakaran D, Padmanabhan S. Implications of discoveries from genome-wide association studies in current cardiovascular practice. World J. Cardiol. 3(7), 230–247 (2011).
  MedlineGoogle Scholar
• 143 Ronald J, Rajagopalan R, Ranchalis JE et al. Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease. Lipids Health Dis. 8, 52 (2009).
  MedlineGoogle Scholar
• 144 Cacabelos R, Goldgaber D, Vostrov A et al. APOE-TOMM40 in the pharmacogenomics of dementia. J. Pharmacogenomics Pharmacoproteomics 5, 135 (2014).•• First paper reporting the influence of TOMM40-APOE variants on AD pharmacogenetics.
  Google Scholar
• 145 Goldman JS, Hahn SE, Catania JW et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet. Med. 13(6), 597–605 (2011).
  MedlineGoogle Scholar
• 146 Schipper HM. Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention. Alzheimers Dement. 7, e118–e123 (2011).
  Medline CASGoogle Scholar
• 147 Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet. Test Mol. Biomarkers 15(12), 871–875 (2011).
  MedlineGoogle Scholar
• 148 Ohara T, Ninomiya T, Kubo M et al. Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: the hisayama study. J. Am. Geriatr. Soc. 59(6), 1074–1079 (2011).
  MedlineGoogle Scholar
• 149 Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 280–292 (2011).
  MedlineGoogle Scholar
• 150 Akinleye I, Roberts JS, Royal CD et al. Differences between African American and white research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease. J. Genet. Couns. 20(6), 650–659 (2011).
  MedlineGoogle Scholar
• 151 Sowell RA, Owen JB, Butterfield DA. Proteomics in animal models of Alzheimer's and Parkinson's disease. Ageing Res. Rev. 8(1), 1–17 (2009).
  Medline CASGoogle Scholar
• 152 Britschgi M, Rufibach K, Bauer Huang SL et al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol. Cell Proteomics 10, M111, 008862 (2011).
  MedlineGoogle Scholar
• 153 Khachaturian ZS, Petersen RC, Gauthier S et al. A roadmap for the prevention of dementia: the inaugural Leon Thal symposium. Alzheimers Dement. 4(3), 156–163 (2008).
  MedlineGoogle Scholar
• 154 Cacabelos R. Role of nutrition in the prevention of Alzheimer's disease. Aging Health 1, 359–362 (2005).
  CASGoogle Scholar
• 155 Crenshaw DG, Gottschalk WK, Lutz MW et al. Using genetics to enable studies on the prevention of Alzheimer's disease. Clin. Pharmacol. Ther. 93(2), 177–185 (2013).
  Medline CASGoogle Scholar
• 156 Gelfand Y, Kaplitt MG. Gene therapy for psychiatric disorders. World Neurosurg. 80(3–4), S32.e11–8 (2012).
  Google Scholar
• 157 Xie Z, Dong Y, Maeda U, Xia W, Tanzi RE. RNAi-mediated knock-down of Dab and Numb attenuate Aβ levels via γ-secretase mediated APP processing. Transl. Neurodegener. 1(1), 8 (2012).
  Medline CASGoogle Scholar
• 158 Cacabelos R, Torrellas C, López-Muñoz F. Epigenomics of Alzheimer's disease. J. Exp. Clin. Med. 6(3), 75–82 (2014).
  CASGoogle Scholar
• 159 Cacabelos R, Torrellas C. Epigenetic drug discovery for Alzheimer's disease. Expert Opin. Drug Discov. 3, 1–28 (2014).
  Google Scholar
• 160 Patel L, Grossberg GT. Combination therapy for Alzheimer's disease. Drugs Aging 28(7), 539–546 (2011).
  Medline CASGoogle Scholar
• 161 Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nat. Genet. 37(7), 671–681 (2005).
  Medline CASGoogle Scholar
• 162 Chang PK, Boridy S, McKinney RA, Maysinger D. Letrozole potentiates mitochondrial and dendritic spine impairments induced by β-amyloid. J. Aging Res. 2013, 538979 (2013).
  MedlineGoogle Scholar
• 163 Janicki SC, Park N, Cheng R, Schupf N, Clark LN, Lee JH. Aromatase variants modify risk for Alzheimer's disease in a multiethnic female cohort. Dement. Geriatr. Cogn. Disord. 35(5–6), 340–346 (2013).
  Medline CASGoogle Scholar
• 164 Friedland RP. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J. Alzheimers Dis. doi:10.3233/JAD-142841 (2015) (Epub ahead of print).
  Google Scholar